Last reviewed · How we verify
mouth rinse
mouth rinse is a Small molecule drug developed by Ministry of Higher Education, Malaysia. It is currently FDA-approved for Control of plaque leading to bleeding gums, Prevention of gingivitis.
Mouth rinse is a liquid held in the mouth to be swirled around and may be gargled, typically by tilting the head back and bubbling the liquid at the back of the mouth. It has been studied as a treatment for various conditions, including gingivitis, head and neck cancer, and postoperative complications, and its mechanism is classified as a DNA disrupting agent.
At a glance
| Generic name | mouth rinse |
|---|---|
| Sponsor | Ministry of Higher Education, Malaysia |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
- Control of plaque leading to bleeding gums
- Prevention of gingivitis
Common side effects
Key clinical trials
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
- Effects of Different Caffeine Forms on Aerobic and Anaerobic Exercise Performance (NA)
- Effect of MI Paste Plus™ on Streptococcus Mutans and White Spot Lesions in Fixed Orthodontics (NA)
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)
- A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mouth rinse CI brief — competitive landscape report
- mouth rinse updates RSS · CI watch RSS
- Ministry of Higher Education, Malaysia portfolio CI
Frequently asked questions about mouth rinse
What is mouth rinse?
What is mouth rinse used for?
Who makes mouth rinse?
What development phase is mouth rinse in?
Related
- Manufacturer: Ministry of Higher Education, Malaysia — full pipeline
- Indication: Drugs for Control of plaque leading to bleeding gums
- Indication: Drugs for Prevention of gingivitis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing